Uterine Fibroids Epidemiology Forecast 2025-2034

Uterine fibroids refer to a noncancerous tumor that form in or on the wall of uterus in women and people assigned female at birth. It is estimated that about 40% to 80% of individuals with a uterus develop fibroids, with a high incidence recorded in people between 30 and 50 years.

Uterine Fibroids Epidemiology Forecast Report Coverage

The “Uterine Fibroids Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of uterine fibroids. It projects the future incidence and prevalence rates of uterine fibroids across various populations. The study covers age and type as major determinants of the uterine fibroids-affected population. The report highlights patterns in the prevalence of uterine fibroids over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of uterine fibroids in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Uterine Fibroids: Disease Overview

Uterine fibroids, also called leiomyomas or myomas, are noncancerous growths that develop from the muscle tissue of the uterus. These benign tumors can grow inside the cavity of uterus, within the wall of uterus, or on the outer surface of uterus. Common symptoms include back pain, heavy menstrual bleeding, pain during sex, and frequent urination. Some fibroids do not cause symptoms. Uterine fibroids are known to grow either as a single nodule or in a cluster.

Uterine Fibroids: Treatment Overview

Treatment for uterine fibroids varies based on the size of the fibroids and the severity of symptoms. Pain relievers (NSAIDs), gonadotropin-releasing hormone agonists (GnRH agonists), and hormonal therapies (progestin-releasing IUDs and birth control pills) are commonly used medications. GnRH agonists help in shrinking uterine fibroids before a surgical procedure. Surgical options include hysterectomy (surgical removal of the uterus) and myomectomy (a surgical procedure to remove fibroids while preserving the uterus), among others.

Epidemiology

The uterine fibroids epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for uterine fibroids by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for uterine fibroids and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that around 40% to 80% of people assigned female at birth have uterine fibroids, occurring most commonly in the ages between 30 and 50.
• As per the Society for Women’s Health Research, approximately 70% of white women and 80% of Black women are likely to develop uterine fibroids by the time they reach 50 years.
• Around 40% to 60% of all hysterectomies are due to uterine fibroids along with nearly 18% to 44% of hysterectomies in young women.
• Studies show that nearly 7 out of 10 White women and 8 out of 10 Black women are affected by one or more uterine fibroids by age 45.

Country-wise Uterine Fibroids Epidemiology

The uterine fibroids epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of uterine fibroids varies significantly between countries due to differences in genetic predisposition, lifestyle factors, environmental exposures, healthcare access, and diagnostic practices. In the United States, an estimated 26 million women between the ages of 15 and 50 are affected by fibroids, as per the Society for Women’s Health Research.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of uterine fibroids based on several factors.
• Uterine Fibroids Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of uterine fibroids are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of uterine fibroids epidemiology in the 8 major markets?
• What will be the total number of patients with uterine fibroids across the 8 major markets during the forecast period?
• What was the country-wise prevalence of uterine fibroids in the 8 major markets in the historical period?
• Which country will have the highest number of uterine fibroids patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of uterine fibroids during the forecast period of 2025-2034?
• What are the currently available treatments for uterine fibroids?
• What are the disease risks, signs, symptoms, and unmet needs of uterine fibroids?

This product will be delivered within 3-5 business days.